A PYMNTS Company

UK: CMA deepens Illumina-Pacific Biosciences probe

By  |  June 27, 2019

Britain’s competition watchdog announced on Thursday, June 27, it would launch an in-depth investigation into the planned US$1.2 billion merger between gene sequencing company Illumina and smaller rival Pacific Biosciences of California.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The Competition and Markets Authority (CMA) stated it would refer the merger to a second phase investigation after the companies refused to address concerns the watchdog had raised last week.

    The CMA’s initial⁠—or first phase—investigation had raised concerns about the deal’s impact on the supply of specialist DNA sequencing systems in the UK.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.